Pyoderma gangrenosum
Pyoderma gangrenosum አልፎ አልፎ የሚያቃጥል የቆዳ በሽታ ሲሆን፣ የሚያሰቃዩ የወይምቀስተኛ በቀስተኛ የሚያድግ ቁስለት ይፈጥራሉ። Pyoderma gangrenosum ተላላፊ አይደለም። ሕክምናዎች ኮርቲኮስትሮይድ፣ ሳይክሎፖሮን ወይም የተለያዩ ሞኖክሎናል ፀረ እንግዳ አካላትን ሊያካትቱ ይችላሉ። ምንም እንኳን በማንኛውም እድሜ ላይ ያሉ ሰዎችን ሊጎዳ ቢችልም፣ በአብዛኛው በ40ዎቹና 50ዎቹ ውስጥ ያሉ ሰዎችን ይጎዳል።
☆ AI Dermatology — Free Service
እ.ኤ.አ. በ 2022 ከጀርመን የስቲፍቱንግ ዋረንቴስት ውጤቶች ፣ በሞዴልደርም የተገልጋዮች እርካታ ከሚከፈልባቸው የቴሌሜዲኬን ምክሮች በትንሹ ያነሰ ነበር።
እ.ኤ.አ. በ 2022 ከጀርመን የስቲፍቱንግ ዋረንቴስት ውጤቶች ፣ በሞዴልደርም የተገልጋዮች እርካታ ከሚከፈልባቸው የቴሌሜዲኬን ምክሮች በትንሹ ያነሰ ነበር።
አልሰርቲቭ ኮላይትስ ያለው ሰው በእግሩ ላይ።
relevance score : -100.0%
ReferencesPyoderma gangrenosum ብርቅዬ የቆዳ በሽታ ሲሆን፣ በቀይ ወይም በነጭ ጠርዝ ላይ የሚታይ የተለየ ቁስለትን ያስከትላል። እንደ ኢንፍላማቶሪ በሽታ ተመድቧል እና ኒውትሮፊል dermatosis የተባለ ቡድን አካል ነው። Pyoderma gangrenosum የሚያሳየው መንስኤ ውስብስብ ነው፤ በጄኔቲክ ተጋላጭ ሰዎች ላይ በተፈጥሮ ወይም በተለዋዋጭ የበሽታ መከላከል ችግሮችን ያካትታል። በቅርቡ ተመራማሪዎች የበሽታው መነሻ ሊሆኑ የሚችሉ የፀጉር መርገጫዎች ላይ ትኩረት አድርገዋል።
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum በጣም አልፎ አልፎ የሚከሰት የቆዳ ህመም እጅግ የሚያምር ቁስለት ነው። የተወሰኑ የበሽታ ተከላካይ ሕዋሳት እንቅስቃሴን እንደሚጨምር እናውቃለን፣ ስለዚህ መንስኤውን ሙሉ በሙሉ እንቆጣጠራለን። በሽታውን ማከም አሁንም ቀላል አይደለም። የተለያዩ መድሃኒቶች አሉ፣ እነሱም የበሽታ መከላከት ስርዓትን የሚቀንሱ ወይም እንቅስቃሴውን የሚያሻሽሉ ናቸው። ከነዚህ ጎን ለጎን ቁስሎችን በማከም እና ህመምን በመቆጣጠር ላይ እናተኩራለን። Corticosteroids እና cyclosporine ብዙውን ጊዜ የመጀመሪያ ምርጫዎች ናቸው፣ ነገር ግን ቅርብ ጊዜ ውስጥ TNF-α አጋቾችን የሚጠቀሙ ባዮሎጂያዊ ሕክምናዎች ተጨማሪ ጥናቶች ተካሂደዋል። እነዚህ ባዮሎጂስቶች በተለይም ሌሎችን የሚያነቃቁ ሁኔታዎች ያሉባቸው ታካሚዎች ላይ እና በበሽታው ሂደት ውስጥ ቀደም ብለው ተጠቅሞ ይጠቀማሉ።
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
